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The lack of a suitable substitute for the greater saphe-
nous vein has led to the exploration of other biological tis-
sues, including umbilical vein and gluteraldehyde or
freeze-dried saphenous vein. Most recently, interest has
again arisen in the use of cryopreserved saphenous vein as
an alternative for distal revascularization in patients with-
out adequate autogenous vein. We have evaluated the
long-term patency and limb-salvage rates for patients
undergoing bypass grafting procedures with cryopre-
served vein grafts.
METHODS
Medical records of all patients undergoing lower
extremity bypass grafting with cryopreserved vein at two
teaching hospitals between 1992 and 1997 were retro-
spectively reviewed. Patients who had undergone more
recent bypass grafting procedures were not evaluated
because of the short period of follow-up available. Patients
undergoing implantation of cryopreserved veins into loca-
tions other than the lower extremities were also excluded
from the review. Demographics, comorbidities, indica-
tions, outflow vessels, previous vascular procedures, and
outcomes were documented. Comorbidities included
coronary artery disease, hypertension, diabetes mellitus,
cerebrovascular disease, hypercholesterolemia, and current
smoking. Follow-up data were obtained from subsequent
admissions and office records. Duplex graft surveillance
frequency varied because of physician preference. Primary
outcomes were death, primary graft patency, and amputa-
tion. Skin integrity and additional bypass grafting proce-
dures were assessed when data were available. Statistical
Autologous saphenous vein remains the ideal conduit
for lower extremity revascularization. However, the saphe-
nous vein is not always available for distal reconstruction
because of earlier harvesting for coronary bypass grafting
or lower extremity revascularization, removal for varicosi-
ties, inadequate vein size, previous phlebitis, or structural
defects within the vein. In as many as 20% of patients, the
ipsilateral saphenous vein is not available or suitable for
grafting.1 The next option for many surgeons is contralat-
eral saphenous vein and then alternative veins, including
the cephalic vein, basilic vein, and lesser saphenous veins.
In 10% of patients, no autogenous tissue is available for
distal reconstruction.1,2 Prosthetic grafts have been used
with reasonable success in the above-knee position, but
they have relatively poor results when used for distal revas-
cularizations.3-5 Multiple techniques have been proposed
to augment the patency of the prosthetic grafts, including
arteriovenous fistula or a variety of cuffs or patches with
small pieces of vein at the distal anastomosis.6-8
Nonetheless, prosthetic grafts remain a poor alternative
for distal reconstructions.
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Purpose: When autogenous vein is unavailable, cryopreserved veins have been used in patients as a means of attempted
limb salvage. We evaluated the long-term patency and limb salvage rates for patients undergoing bypass grafting with
cryopreserved veins.
Methods: Medical records were reviewed for patients undergoing cryovein bypass grafting at two hospitals from 1992
to 1997. Follow-up data were obtained from subsequent admissions and office records. Primary outcomes were death,
amputation, and primary patency. Skin integrity and additional bypass grafting procedures were assessed when data
were available. Analysis was performed by means of life-table and χ2 analyses with the Statistical Package for Social
Sciences (SPSS).
Results: Seventy-six patients (mean age, 70 ± 11 years) underwent 80 procedures. Indications for surgery were tissue
loss (63%), rest pain (24%), acute ischemia (11%), and other (2%). Early complications included 3 deaths (4%), 14 acute
thromboses (18%), and 7 major amputations (9%). The mean follow-up period was 17.8 ± 20.89 months (range, 0-77
months). The primary patency rate was determined to be 36.8% at 1 year and 23.6% at 3 years by means of life-table
analysis. The limb salvage rate was 65.5% at 1 year and 62.3% at 3 years. Skin integrity was found to be compromised
in 17 (55%) of 31 patients who were available to follow-up. Nine patients (11.3%) underwent additional ipsilateral
revascularization or revisions, with one of three of these patients eventually requiring a major amputation.
Conclusion: Cryopreserved vein may be a reasonable alternative conduit for limb salvage when no autogenous tissue is
available; it has an acceptable limb salvage rate (62.3%) at 3 years. Long-term patency remains relatively poor, with only
23.6% of originally placed grafts patent at 3 years. The use of cryopreserved veins should be strictly confined to limb
salvage after a thorough search for autogenous tissue has been exhausted. (J Vasc Surg 2001;33:528-32.)
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analysis was performed by means of life-table and χ2 analy-
ses with SPSS (Statistical Package for Social Sciences), with
significance taken when the P value was less than .05.
RESULTS
Seventy-six patients (mean age, 70 ± 11 years; range,
37-88 years) underwent 80 procedures. Thirty-seven
patients (49%) were men. Comorbidities included coro-
nary artery disease (39%), hypertension (36%), diabetes
mellitus (54%), cerebrovascular disease (19%), hypercho-
lesterolemia (20%), and current smoking (18%). Almost
half the patients (46%) had undergone an earlier ipsilateral
bypass grafting procedure. Indications for surgery were
tissue loss (63%), rest pain (24%), acute ischemia (11%),
and other (2%). Other indications included infection.
Outflow vessels included the popliteal (31%), tibial (60%),
and plantar (9%).
The patient survival rate was 90.8% at 1 year and
63.4% at 3 years (Fig 1). Early complications occurred
after 17 bypass grafting procedures (21%) and included 3
deaths (4%), 14 acute thromboses (18%), and 7 major
amputations (9%). Postoperative occlusion was a predictor
of limb loss (P = .00007), with 71% of patients (10 of 14)
with postoperative occlusion undergoing major amputa-
tion within 6 months of surgery. The remaining four
patients (29%) with postoperative occlusion had viable
limbs at a mean of 4.8 months postoperatively. However,
two of these patients had no evidence of healing of their
original tissue loss 5 months after surgery. 
The mean follow-up period was 17.8 ± 20.89 months
(range, 0-77 months). The primary patency rate, as doc-
umented with duplex examination, was 36.8% at 1 year
and 23.6% at 3 years by means of life-table analysis (Fig
2). Data were insufficient to make determinations about
differences in cumulative patency for femoral popliteal
versus femoral distal bypass grafts, because of sample size.
The overall limb salvage rate was 65.5% at 1 year and
62.3% at 3 years (Fig 3). Incidence of major amputation
was significantly increased with femoral distal bypass
grafting, as opposed to femoral popliteal bypass grafting
(49% vs 12% at 3 years; P = .02; Fig 4). Additional bypass
grafting procedures were completed in 11.3% of patients
(9 of 80). The limb salvage rate at 6 months did not dif-
fer significantly in patients with primarily patent grafts
versus patients with secondarily patent grafts (93.4% vs
100%; P = .16). However, one third of patients who
underwent additional ipsilateral revascularization eventu-
ally required a major amputation. A significant difference
in limb salvage rate was seen between primarily patent
grafts and occluded grafts that were not subjected to
additional procedures (93.4% vs 45.2%; P = .0001).
Additionally, a significant difference was noted between
secondarily patent grafts and occluded grafts (100% vs
45.2%, P = .04; Fig 5).
Ulceration was seen in 17 (55%) of 31 patients who
were available for follow-up. Five of those patients (16%)
were documented to have no evidence of healing of the
original tissue loss within 6 months of surgery. New tissue
loss was demonstrated in the remaining patients during
the course of follow-up. The bypass graft was occluded in
most patients with ulceration (11 of 17).
DISCUSSION
Short-term reports have often suggested widely vary-
ing outcomes for allograft bypass grafts.9-18 Fewer series
that analyze long-term outcomes are available. Further
confounding the analysis of outcome are differences in
methods of preservation. Old data are based on different
Fig 1. Life-table analysis of cumulative patient survival rate.
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techniques of cryopreservation with different cryoprotec-
tant solutions. Uniformity in cryopreservation techniques
still does not exist. Although techniques are not as varied,
with most cryopreserved veins being purchased from one
of several major commercial sources, there are still differ-
ences between these companies that may have an impact
on short- and long-term outcomes. Other confounding
factors are variability in patient population between series
and the use of pharmacological adjuncts, including war-
farin and various immunosuppressive agents.
Short-term patency rates from recent series in the lit-
erature range from 28% to 80% at 1 year and fall to
between 19% and 42% at 2 years. Complications related to
implantation of cryopreserved venous allografts include an
early failure rate (fewer than 30 days) of 17% and a late
aneurysm formation rate of between 5% and 33% in
reported series.9-19
Unfortunately, there are still relatively few studies with
any long-term results, which makes conclusions on long-
term patency data difficult. We found a long-term patency
Fig 2. Life-table analysis of cumulative primary patency rate of cryopreserved vein bypass grafts.
Fig 3. Life-table analysis of limb-salvage rate.
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rate of 23.6% at 3 years, with a 62.3% rate of limb salvage.
Further, additional attempts at revascularization for
occluded grafts did not improve the overall limb salvage
rate in the long term. The outcome of limb salvage
surgery in the absence of suitable autologous saphenous
vein depends greatly on the material used for bypass graft-
ing.20-24 It is difficult to appropriately compare cryopre-
served vein bypass grafts with prosthetic bypass grafts,
because there are no randomized trials comparing the two
conduits. In historical studies, surgeons may preferentially
use allograft vein for patients with disadvantaged outflow
or more distal sites, thereby making comparisons ques-
tionable. Patency rates of prosthetic to below-knee
popliteal bypass grafts range from 44% to 60%3,5,20,23,24 at
5 years. However, patency rates of prosthetic bypass grafts
to tibial vessels has generally been unsatisfactory, with only
a 12% to 22% patency rate at 5 years.3
Cryopreserved vein grafts may be a reasonable alter-
native to prosthetic grafts for limb salvage procedures
when no autogenous tissue is available. Limb salvage rates
are acceptable, both in the short term and the long term.
However, skin integrity may remain compromised or
recur, casting doubts on the long-term efficacy of bypass
grafting with cryopreserved veins. The use of cryopre-
served veins should be confined to limb-salvage proce-
dures. Cryopreserved veins should be used only after a
thorough search for autogenous tissue has been
exhausted. Further, the use of polytetrafluoroethylene
Fig 4. Life-table analysis of cumulative limb-salvage rate for femoral popliteal versus distal bypass grafting procedures (P = .02).
Fig 5. Life-table analysis of cumulative limb-salvage rate for primarily patent, secondarily patent, and occluded bypass grafts. Primarily
patent versus secondarily patent, P = .16; primarily patent versus occluded without additional bypass, P = .0001; secondarily patent ver-
sus occluded without additional bypass, P = .04. BPG, Bypass graft; OCCL, occlusive.
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grafts with adjunctive cuffs or patches should be strongly
considered before implantation of a cryopreserved graft.
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